EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC-ND 4.0

Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma

Chio Sakai, Masashi Matsuyama, Masayuki Nakajima, Sosuke Matsumura, Mizu Nonaka, Naoki Arai, Kenya Kuramoto, Kazufumi Yoshida, Yuko Morishima, Masafumi Muratani, Nobuyuki Hizawa

Allergology International · 2024

DOI: 10.1016/j.alit.2024.03.005 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Allergology International, 2024. Verfasst von Chio Sakai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Eosinophils, Phenotype. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GSK, GlaxoSmithKline Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study was funded by GlaxoSmithKline in their investigator sponsored studies (ISS) scheme (Study ID 213388).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAsthmaEosinophilsPhenotypeAnti-Asthmatic AgentsHumansMaleFemaleMiddle AgedEosinophiliaAdultLeukocyte CountTreatment OutcomeSeverity of Illness Index

Substanzen

mepolizumabAntibodies, Monoclonal, HumanizedAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
  • Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan. Electronic address: mmatsuyama@md.tsukuba.ac.jp.
  • Department of Genome Biology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Förderung

  • GSK
  • GlaxoSmithKline Japan

Zitieren

APA

Sakai, C., Matsuyama, M., Nakajima, M., Matsumura, S., Nonaka, M., Arai, N., Kuramoto, K., Yoshida, K., Morishima, Y., Muratani, M., & Hizawa, N. (2024). Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma. Allergology International. https://doi.org/10.1016/j.alit.2024.03.005

Vancouver

Sakai C, Matsuyama M, Nakajima M, Matsumura S, Nonaka M, Arai N, et al. Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma. Allergology International. 2024. doi:10.1016/j.alit.2024.03.005

BibTeX
@article{Sakai2024,
  author = {Sakai, Chio and Matsuyama, Masashi and Nakajima, Masayuki and Matsumura, Sosuke and Nonaka, Mizu and Arai, Naoki and Kuramoto, Kenya and Yoshida, Kazufumi and Morishima, Yuko and Muratani, Masafumi and Hizawa, Nobuyuki},
  title = {Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma},
  journal = {Allergology International},
  year = {2024},
  doi = {10.1016/j.alit.2024.03.005}
}
Kostenlos starten →